Stock ATHJF PERCHERON THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Percheron Therapeutics Limited OTC Markets

Equities

ATHJF

AU0000317281

Delayed OTC Markets
Other stock markets
 16:09:57 31/05/2024 BST 		5-day change 1st Jan Change
0.012 USD -84.00% Intraday chart for Percheron Therapeutics Limited -.--% +20.00%
06-17 Percheron Therapeutics Appoints CFO MT
06-03 Percheron Therapeutics Names Chief Medical Advisor MT

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PERCHERON THERAPEUTICS LIMITED Stock Percheron Therapeutics Limited
+20.00% 48.02M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.09% 122B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+15.93% 113B
B+
ARGENX SE Stock argenx SE
+17.55% 26.22B
B
BIONTECH SE Stock BioNTech SE
-24.07% 19.01B
B+
GENMAB A/S Stock Genmab A/S
-19.14% 15.71B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.91% 15.22B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.81% 14.72B
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.60% 14.58B
C+
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.88% 13.84B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PER Stock
  4. ATHJF Stock
  5. Ratings Percheron Therapeutics Limited